The DOI matches its Crossref record.
Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial
Abstract
OBJECTIVE: The clinical use of cisplatin chemotherapy is limited by severe peripheral neurotoxicity reported in up to 90% of patients receiving a cumulative dose higher than 300 mg/m(2). The present study evaluates the neuroprotective effect of antioxidant supplementation (vitamin E) in patients treated with cisplatin chemotherapy. METHODS: A total of 108 patients treated with cisplatin chemotherapy were randomly assigned to receive vitamin E supplementation (alpha-tocopherol 400 mg/day) or placebo. Treatment was started orally before chemotherapy and continued for 3 months after the suspension of cisplatin. RESULTS: Of 108 randomized patients, 68 received at least one clinical and neurophysiologic examination after cisplatin CT; 41 patients received a cumulative dose of cisplatin higher than 300 mg/m(2) and were eligible for statistical analysis: 17 in the vitamin E group (group 1) and 24 in the placebo group (group 2). The incidence of neurotoxicity was significantly lower in group 1 (5.9%) than in group 2 (41.7%) (p < 0.01). The severity of neurotoxicity, measured with a validated neurotoxicity score (Total Neuropathy Score [TNS]), was significantly lower in patients receiving vitamin E than those receiving placebo (mean TNS 1.4 vs 4.1; p < 0.01). CONCLUSIONS: This phase III study confirms the neuroprotective role of vitamin E against cisplatin peripheral neurotoxicity. Vitamin E supplementation should be adopted in patients receiving cisplatin-based chemotherapy. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that vitamin E supplementation significantly reduces the relative risk of developing signs or symptoms of neurotoxicity (relative risk = 0.14) (95% confidence interval = 0.02-1.00, p < 0.05).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Greenlee, H., DuPont‐Reyes, M. J., Balneaves, L. G., Carlson, L. E., Cohen, M. R., Deng, G., Johnson, J. A., Mumber, M., Seely, D., Zick, S. M., et al. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21397 · Cited by 768
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Metadata
- Authors
- Pace, A., Giannarelli, D., Galiè, E., Savarese, A., Carpano, S., Della Giulia, M., Pozzi, A., Silvani, A., Gaviani, P., Scaioli, V., Jandolo, B., Bove, L., & Cognetti, F.
- Venue
- Neurology
- Published
- 2010-03-02
- Volume
- 74
- Issue
- 9
- Pages
- 762-766
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1974595904
- Cited by
- 191
- References
- 0
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181d5279e
- The paper
- Pace, A., Giannarelli, D., Galiè, E., Savarese, A., Carpano, S., Della Giulia, M., Pozzi, A., Silvani, A., Gaviani, P., Scaioli, V., Jandolo, B., Bove, L., & Cognetti, F. (2010). Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology. https://doi.org/10.1212/wnl.0b013e3181d5279e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.